Oral composition and anticancer composition comprising culture supernatant of escherichia coli

The use of a non-toxic culture supernatant from a ypjD mutant Escherichia coli strain addresses inefficiencies in tetrapyrrole compound production and opens new applications in pharmaceuticals and food, demonstrating anti-cancer efficacy.

WO2026240155A1PCT designated stage Publication Date: 2026-11-19SIXONPOWER CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2026/018200
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-14
Filing Date
2026-05-14
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing technologies do not utilize the culture supernatant of Escherichia coli for bioapplications, particularly in pharmaceutical and food applications, and the production methods for tetrapyrrole compounds are inefficient and environmentally impactful.

Method used

A non-toxic culture supernatant of a ypjD mutant Escherichia coli strain is used, which is safe for consumption and exhibits anti-cancer activity, produced through a method that does not require cell lysis or precursor addition, allowing for a simpler and more environmentally friendly process.

Benefits of technology

The culture supernatant is non-toxic and effective against various types of cancer, including solid and hematological cancers, with a demonstrated safety profile and anti-cancer efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JPOXMLDOC01-APPB-M000008
    Figure JPOXMLDOC01-APPB-M000008
  • Figure JPOXMLDOC01-APPB-M000009
    Figure JPOXMLDOC01-APPB-M000009
  • Figure JPOXMLDOC01-APPB-T000001
    Figure JPOXMLDOC01-APPB-T000001
Patent Text Reader

Abstract

The problem to be solved by the present invention is to provide technology for using a culture supernatant of a ypjD mutant strain in vivo. The means for solving this problem is the use, as an oral composition, of a culture supernatant of Escherichia coli in which the gene ypjD (b2611) is no longer able to be expressed due to mutation.
Need to check novelty before this filing date? Find Prior Art

Description

Oral composition and anticancer composition containing culture supernatant of Escherichia coli

[0001] This invention relates to an oral composition containing the culture supernatant of Escherichia coli and its uses.

[0002] Tetrapyrrole compounds, typified by porphyrins, are important functional substances not only for pharmaceutical applications such as anticancer drugs, but also as food additives and in the fields of electronics as redox catalysts, photocatalysts, and electron transfer media. These compounds have traditionally been produced mainly through chemical synthesis, but this method has presented challenges such as limitations in manufacturing equipment and catalysts, as well as the environmental impact of the solvents used.

[0003] Against this backdrop, methods for producing tetrapyrrole compounds using microorganisms are attracting attention. For example, methods for obtaining protochlorophyllide using mutant strains of the photosynthetic bacterium Plectonema (Patent Document 1), methods for recovering tetrapyrrole compounds by culturing photosynthetic bacteria (Patent Documents 2 and 3), and methods for obtaining uroporphyrin by culturing microorganisms of the genus Arthrobacter (Patent Document 4) are known.

[0004] However, these methods often require steps such as cell lysation or extraction to obtain the active ingredient from the culture, or the addition of 5-aminolevulinic acid, a precursor of tetrapyrrole compounds, to the culture medium, which presents challenges in terms of manufacturing efficiency and ease of process.

[0005] To address these challenges, Patent Document 5 discloses a method for recovering tetrapyrrole compounds secreted into a culture medium by culturing Escherichia coli in which the gene ypjD(b2611) has been mutated and is no longer expressible, in a nutrient-poor medium. This method is superior in that it does not require the addition of precursors and allows the target product to be obtained without disrupting the bacterial cells, thus simplifying the process and reducing the environmental impact.

[0006] On the other hand, while stem cell culture supernatants are being used in pharmaceutical applications for regenerative medicine and immune regulation, the idea of ​​directly applying E. coli culture supernatant to living organisms has not existed in previous technologies. Even in Patent Document 5, the culture supernatant of the ypjD mutant strain is treated solely as a means of producing and recovering tetrapyrrole compounds, and the possibility of using the culture supernatant itself as a functional composition is not mentioned.

[0007] JP-A-5-91866 JP-A-5-244937 JP-A-2000-23691 JP-A-5-38295 Patent No. 4339397

[0008] The technology of using recombinant proteins biosynthesized by E. coli for pharmaceutical applications has existed for a long time. However, this technology presupposes the purification of the useful substances biosynthesized by E. coli, and does not involve the direct use of the culture supernatant. E. coli has a strong image as a pathogen, and the idea of ​​directly applying its culture supernatant to living organisms did not even exist in conventional technology.

[0009] On the other hand, according to the technology described in Patent Document 5, a culture supernatant containing a tetrapyrrole compound can be obtained, but the only listed application fields are optical storage media, information storage media, electron transfer media, semiconductor devices, and electrodes.

[0010] In view of the above, the problem that the present invention aims to solve is to provide a technology for the bioapplication of the culture supernatant of the ypjD mutant strain.

[0011] Through the diligent research efforts of the inventors, it was discovered that the culture supernatant of the ypjD mutant strain is non-toxic and safe for consumption. Furthermore, anti-cancer activity was also found in this culture supernatant. The present invention was completed based on these findings and is described below.

[0012] [Item 1] An oral composition comprising the culture supernatant of Escherichia coli in which the gene ypjD(b2611) is unable to be expressed due to a mutation. [Item 2] The composition according to Item 1, which is a beverage. [Item 3] The composition according to Item 1 or 2, comprising the culture supernatant. [Item 4] The composition according to any one of Items 1 to 3, which is an anticancer composition. [Item 5] An anticancer composition comprising the culture supernatant of Escherichia coli in which the gene ypjD(b2611) is unable to be expressed due to a mutation.

[0013] The oral composition of the present invention is non-toxic, safe to drink, and exhibits anti-cancer effects.

[0014] The Escherichia coli used in this invention is a strain in which the gene ypjD(b2611) is unable to be expressed due to a mutation. In this specification, Escherichia coli in which the gene ypjD(b2611) is unable to be expressed due to a mutation may be simply referred to as "mutant Escherichia coli."

[0015] As the mutant E. coli, it is preferable to use mutant E. coli derived from non-pathogenic E. coli. Examples of non-pathogenic E. coli include MG1655, W3110, W1485, DH1, DH5α, DH10B, JM101, JM103, JM105, JM107, JM109, JM110, TOP10, TOP10F', XL1-Blue, XL10-Gold, HB101, MC1061, MC4100, C600, BW25113, NEB 5-alpha, NEB 10-beta, Mach1, Stbl2, Stbl3, Stbl4, SURE, and SURE. 2. K12 series such as AB1157, MRE600, BL21, BL21(DE3), BL21(DE3)pLysS, BL21(DE3)pLysE, BL21-AI, BL21 Star, BLR(DE3), Rosetta, Rosetta 2, Rosetta-gami, Origami, Origami 2, Tuner, Lemo21(DE3), C41(DE3), C43(DE3), SHuffle, SHuffle T7, ER2566, NiCo21(DE3), HMS174 and other B series, C series such as ATCC 8739, W series such as ATCC 9637, Nissle Examples include probiotic strains such as 1917, and conjugation transmission strains such as S17-1, SM10, WM3064, MFDpir, and β2163.

[0016] Specifically, examples of mutant E. coli include E. coli derived from the K12 strain and the B strain. For example, mutant E. coli derived from the K12 strain is preferably used.

[0017] Examples of mutant E. coli strains include transposon insertion mutants of the gene ypjD(b2611). In these mutants, the expression of the gene ypjD(b2611) is partially or completely deleted. The K12 strain can be obtained from, for example, National BioResource, and the BL21 strain can be obtained from, for example, Takara Bio. Another example of a transposon insertion mutant of the gene ypjD(b2611) is JD23504, which is available from National BioResource.

[0018] Various known culture media can be used to culture the mutant Escherichia coli used in the present invention. The culture medium is not particularly limited as long as it contains nutrients suitable for the growth of Escherichia coli, and synthetic media, semi-synthetic media, or natural media can be appropriately selected.

[0019] Specifically, examples include Luria-Bertani (LB) medium, Terrific Broth (TB) medium, M9 minimal medium, SOC medium, and NB medium (Nutrient Broth), and the appropriate medium can be selected depending on the purpose and culture stage (pre-culture or main culture). For example, one embodiment involves performing pre-culture using nutrient-rich LB medium in the initial growth stage, and then switching to a nutrient-poor medium with restricted nutrients for main culture.

[0020] The components of the culture medium can be adjusted according to the growth requirements of the target E. coli. Carbon sources can include glucose, lactose, glycerol, etc., and nitrogen sources can include amino acids, peptone, yeast extract, etc. Furthermore, by appropriately including phosphate buffers, inorganic salts, trace elements, vitamins, etc., a stable culture environment can be provided.

[0021] Since the objective of the present invention is to utilize a composition containing the culture supernatant obtained by culturing Escherichia coli, it is desirable to design the culture medium in a way that ensures no unwanted contaminants remain in the final supernatant.

[0022] In this embodiment, a compound containing a metal element that becomes an ion in the medium or a metal element that dissociates as an ion can be added to a nutrient-poor medium to obtain a tetrapyrrole compound or complex containing this metal. The metal can be any metal that becomes an ion in the medium. Compounds containing such metals are soluble in acidic, alkaline, or neutral aqueous solutions. Examples of the metal element include at least one metal selected from the group consisting of gold (Au), copper (Cu), potassium (K), manganese (Mn), zinc (Zn), and ruthenium (Ru). The metal can also be added in the form of an inorganic metal compound or an organometallic compound. Examples of inorganic metal compounds include sulfates, carbonates, nitrates, thiosulfates, oxides, nitrides, or halides of the above metals. Examples of organometallic compounds include sodium goldthiomalate and zinc malate.

[0023] The culture conditions for mutant E. coli can be the same as those for E. coli. This is true whether E. coli is pre-cultured and then cultured in a nutrient-poor medium. For example, pre-culture can be performed using LB medium at a temperature of 15°C to 40°C for 6 to 24 hours, and then the resulting cell suspension can be cultured in a nutrient-poor medium at a temperature of 20°C to 40°C for 12 to 96 hours.

[0024] After the culture is complete, the obtained culture is treated by centrifugation to precipitate the mutated E. coli cells. This allows for the separation and recovery of the supernatant (culture supernatant) that does not contain bacterial cells. The composition according to the present invention contains the culture supernatant of E. coli obtained by this method, and the supernatant contains the physiologically active component that is the target of the present invention.

[0025] The conditions for centrifugation (rotation speed, time, temperature, etc.) can be appropriately set by those skilled in the art based on their knowledge of normal microbial culture. For example, microbial cells can be efficiently precipitated and removed by centrifugation at a range of 5,000 to 15,000 × g for several minutes to several tens of minutes at room temperature or low temperature conditions (4 to 25°C).

[0026] In this specification, "culture supernatant" includes not only the culture supernatant itself, but also compositions obtained by processing the culture supernatant through filtration, sterilization, concentration, drying, powdering, etc. Therefore, the clear supernatant obtained by the above operations can be used as is, or, if necessary, processed through filtration, sterilization, drying, powdering, etc., as the oral composition of the present invention.

[0027] The oral composition of the present invention may be in the form of consisting only of the culture supernatant of mutant Escherichia coli. Alternatively, it may be in the form of diluting the culture supernatant of mutant Escherichia coli with water or other orally ingestible media. When diluted, the content of the culture supernatant of mutant Escherichia coli in the oral composition of the present invention is not particularly limited and can be, for example, 10% by mass or more, 20% by mass or more, 30% by mass or more, 40% by mass or more, 50% by mass or more, 60% by mass or more, 70% by mass or more, 80% by mass or more, or 90% by mass or more.

[0028] Furthermore, optional components commonly used in the food or pharmaceutical fields may be added to the culture supernatant of mutant Escherichia coli or its dilution. For example, optional components that may be added include the following, for the purpose of improving preservation, taste, color, aroma, stability, processability, or the absorption and release of active ingredients.

[0029] In food applications, examples include sugars (e.g., glucose, fructose, lactose, maltose, dextrin, etc.), polysaccharides (e.g., alginic acid, agar, xanthan gum, etc.), proteins (e.g., gelatin, casein, etc.), oils and fats (e.g., vegetable oil, medium-chain triglyceride oil, etc.), emulsifiers, acidulants, flavorings, colorings, sweeteners, preservatives, antioxidants, dietary fiber, vitamins, minerals, amino acids, fermentation-derived components, and probiotics such as lactic acid bacteria and bifidobacteria.

[0030] In pharmaceutical applications, buffers, excipients, binders, disintegrants, lubricants, suspending agents, surfactants, stabilizers, preservatives, pH adjusters, enteric coatings, absorption enhancers, sustained-release agents, flavor enhancers, antioxidants, physiologically active adjuvants, prodrug components, etc., may be used.

[0031] These optional components are selected and used as appropriate in the composition of the present invention, to the extent that they do not impair the effects of the invention, and are prepared according to the dosage form of the composition (liquid, powder, granules, tablets, capsules, jelly, beverage, etc.) and the intended use.

[0032] The oral composition of the present invention can be commercialized as a beverage, in which case various components known in the food industry can be optionally added to enhance usability and palatability.

[0033] Examples of optional ingredients that can be added include sugars (glucose, fructose, oligosaccharides, etc.), acidulants (citric acid, malic acid, etc.), flavorings (fruit-based, herb-based, etc.), colorings (naturally derived or synthetic colorings permitted as food additives), sweeteners (sucralose, stevia, etc.), vitamins (vitamin C, B vitamins, etc.), minerals (calcium, magnesium, etc.), amino acids (glutamic acid, arginine, etc.), functional ingredients (lactic acid bacteria, dietary fiber, polyphenols, etc.), preservatives, antioxidants, etc.

[0034] The product can be filled into containers suitable for beverage use, such as PET bottles, cans, glass bottles, pouches, paper cartons, and stick packaging (a form in which the powder is dissolved and consumed). To prevent the contents from becoming disorganized due to light and oxygen, it is desirable to use containers that have light-shielding or barrier properties. Furthermore, when filling the container with the composition of the present invention, an embodiment may be adopted in which an inert gas such as nitrogen gas or argon gas is filled into the headspace of the container to prevent deterioration.

[0035] Furthermore, considering long-term storage and portability, it is also possible to manufacture it as a concentrated liquid or powder beverage, which can be diluted with water or other liquids before consumption.

[0036] These components allow the compositions of the present invention to have a wide range of applications as functional beverages, supplement beverages, nutritional supplement beverages, or general soft drinks.

[0037] The composition of the present invention exerts an anticancer effect as described in the Examples below. Therefore, the composition of the present invention can be applied to anticancer uses. The applicable types of cancer include both solid cancers and hematological cancers, for example, gastric cancer, colorectal cancer, rectal cancer, esophageal cancer, hepatocellular carcinoma, biliary tract cancer, pancreatic cancer, lung cancer (non-small cell lung cancer, small cell lung cancer), breast cancer, prostate cancer, bladder cancer, renal cancer, cervical cancer, endometrial cancer, ovarian cancer, brain tumor (glioma, neuroglioma, etc.), skin cancer (malignant melanoma, etc.), solid cancers such as head and neck cancer, and further hematological cancers such as leukemia (acute / chronic, myeloid / lymphoid), malignant lymphoma, and multiple myeloma. These are merely examples, and it goes without saying that the composition of the present invention is also applicable to other cancer types as long as it exhibits an anticancer effect.

[0038] The anticancer composition of the present invention can be used for the purpose of treating and / or preventing cancer. In addition, an embodiment in which it is used in combination with standard cancer treatment can also be adopted.

[0039] The dose of the oral composition of the present invention is not particularly limited. For adults, the upper limit of the volume of the culture supernatant itself can be, for example, 6 L or less per day, and it is preferably ingested at a reference of 20 mL to 1,000 mL per day, or 50 mL to 500 mL. This composition is intended to be drunk continuously for the purposes of health support, physical condition management, or anticancer use, and it is desirable to be ingested continuously every day for a period of 1 month or longer, preferably 6 months or longer, more preferably 1 year or longer. The specific dose and ingestion period can be appropriately adjusted according to age, body weight, health condition, ingestion purpose, presence or absence of concomitant drugs and supplements, and the like, and the composition can also be ingested in multiple divided portions per day.

[0040] The present invention is not limited to the above-described embodiments, and various modifications can be made without departing from the gist of the present invention. Hereinafter, Examples of the present invention will be described.

[0041] <Production Example 1> Transposon insertion mutant strains of the E. coli gene ypjD (b2611) (National BioResource JD23504) or K12 strain were pre-cultured in LB medium (Bacto-tryptone: 1%, Bacto-yeast extract: 0.5%, NaCl: 0.5%) at 37°C for 12 hours. 500 μL of each resulting cell suspension was then cultured in minimal A medium (1.05% (w / v) K 2 HPO 4 , 0.45% (w / v) KH 2 PO 4 , 0.1% (w / v) (NH 4 ) 2SO 4 , 0.05% (w / v) sodium citrate・2H 2 O, 0.32% (w / v) gluocose was added to 500 mL and cultured with shaking at 37°C and a speed of 150 rpm. The cultured E. coli was centrifuged after incubation to precipitate the E. coli, and the clear supernatant (culture supernatant) was collected.

[0042] Tests 1 to 6 were conducted using the culture supernatant prepared in Production Example 1 as the test solution, with the aim of confirming that it was non-toxic.

[0043] <Test Example 1> Acute Toxicity Oral Test Using Rats (1) Method The test was commissioned to the Tama Laboratory of the Japan Food Research Laboratories. BrlHan: WIST@Jcl (GALAS) rats (hereinafter simply referred to as rats) were fasted for approximately 18 hours. Next, the test solution prepared in Production Example 1 or sterile water for injection (Japanese Pharmacopoeia) was orally administered to groups of five male or female rats at a dose of 10 mL / kg using a gastric tube. Water supply was resumed 4 hours after oral administration. General condition was observed once a day for 14 days after administration. Body weight was also measured 7 and 14 days after administration. Then, 14 days after administration, the rats were anesthetized by inhalation of isoflurane, and euthanized by bleeding from the abdominal aorta. After euthanasia, the thoracic and abdominal cavities of the rats were examined macroscopically.

[0044] (2) Results: No rats died in either the male or female rat group administered the test solution of Production Example 1 or sterile water for injection. Furthermore, no abnormalities were observed in general condition.

[0045] The results of the weight measurements are shown in Table 1 below. No significant difference in weight was observed in either the male or female rat group administered the test solution of Production Example 1 or sterile water for injection. For statistical analysis, a test for equal variances was performed. If no significant difference was found, student's t-test was performed; if a significant difference was found, Welch's t-test was performed.

[0046]

[0047] (3) Discussion No abnormalities were observed in the rats administered the test solution of Production Example 1. Therefore, it was found that the test solution of Production Example 1 does not exhibit acute toxicity. Furthermore, it was found that the LD50 (50% Lethal Dose) of the test solution of Production Example 1 was 10 mL / kg or higher.

[0048] <Test Example 2> 28-Day Repeated-Dose Toxicity Study Using Rats (1) Method The study was conducted by the Tama Laboratory of the Japan Food Research Laboratories. The test solution prepared in Manufacturing Example 1 or water for injection (Japanese Pharmacopoeia) was orally administered to groups of six male or female rats at a dose of 8.3 mL / kg once daily for 28 consecutive days using a gastric tube. The day on which administration began was designated as day 0.

[0049] The following observations were made during the administration period: (a) General condition was observed before and after administration during the administration period (28 days). (b) Body weight was measured once a day during the administration period. (c) The amount of food given and the amount of leftover food the following day were measured once a week, and the daily amount of food consumed was calculated. (d) Natural urine collection was performed on the 27th day after the start of administration, and a urinalysis was performed. (e) On the 28th day after the start of administration, rats were anesthetized by inhalation of isoflurane, blood was collected from the posterior vena cava, and hematological and blood biochemical tests were performed. (f) After blood collection, the rats were euthanized by draining blood from the abdominal aorta. After euthanasia, all organs of the rats were removed and observed macroscopically. The weight of each organ was also measured, and the specific weight per 100g of body weight was calculated. (g) Pathological tissue specimens were prepared using the removed organs, and histopathological examinations were performed.

[0050] (2) Results (a) Observation of general condition Regardless of the administered solution, there were no deaths in any of the animals. Furthermore, no abnormalities were observed in the general condition.

[0051] (b) Body weight The results of body weight measurements on days 0, 7, 14, and 28 are shown in Table 2 below. No significant difference in body weight was observed in either the male or female rat group administered the test solution of Production Example 1 or sterile water for injection. For statistical analysis, a test of equal variances was performed. If no significant difference was found, student's t-test was performed; if a significant difference was found, Welch's t-test was performed.

[0052]

[0053] (c) Food intake The results of food intake on days 6, 13, 21, and 26 are shown in Table 3 below. No significant difference in food intake was observed in either male or female rats administered the test solution of Production Example 1 or sterile water for injection. For statistical analysis, a test of equal variances was performed. If no significant difference was found, student's t-test was performed; if a significant difference was found, Welch's t-test was performed.

[0054]

[0055] (d) Urinalysis The results of the urinalysis are shown in Table 4 below. No significant differences were observed in any of the urinalysis items in the rat groups administered either the test solution of Production Example 1 or sterile water for injection, in both male and female rats. The Mann-Whitney test was used for statistical analysis.

[0056]

[0057] (e) Hematological and blood biochemical tests The hematological tests are shown in Table 5 below, and the blood biochemical tests are shown in Table 6 below. No significant differences were observed in any of the hematological and blood biochemical tests in the rat groups administered either the test solution of Production Example 1 or sterile water for injection, in both male and female rats. For statistical analysis, a test for equal variances was performed. If no significant difference was found, student's t-test was performed; if a significant difference was found, Welch's t-test was performed.

[0058]

[0059]

[0060] (f) Organ Weights The results of the specific weight per 100g of body weight of various organs are shown in Table 7. No significant differences were observed in the specific weight per 100g of body weight of various organs in rat groups administered with either the test solution of Production Example 1 or sterile water for injection, in both male and female rats. For statistical analysis, a test of equal variances was performed, and if no significant difference was found, a student's t-test was performed; if a significant difference was found, a Welch's t-test was performed. Furthermore, no abnormalities were observed in either male or female rats during macroscopic examination.

[0061]

[0062] (g) Histopathological examination: In the male rat group administered the test solution prepared in Manufacturing Example 1, localized or diffuse mononuclear cell infiltration was observed in the prostatic stroma in 3 cases. Of these, one case was accompanied by cell debris in the abdominal cavity. In addition, localized adipocyte clusters in the stroma were observed in the medulla of the left kidney in 1 case.

[0063] In male rats administered with sterile water for injection, localized or diffuse mononuclear cell infiltration was observed in the prostatic interstitium in two cases. One of these cases was accompanied by cell debris in the abdominal cavity. In female rats administered with sterile water for injection, renal pelvis dilation was observed in one case in the medulla of the left kidney. No abnormalities were observed in female rats administered with the test solution prepared in Manufacturing Example 1.

[0064] (3) Discussion No deaths or abnormalities in general condition were observed in rats administered the test solution of Production Example 1. Furthermore, no significant differences were observed in body weight, food intake, urinalysis, blood biochemistry tests, or relative weight of various organs depending on the administered solution. In addition, some significant differences were observed in hematological tests, but these were minor changes and are not considered to be due to toxicity from the test solution prepared in Production Example 1.

[0065] Macroscopic examination of all organs revealed no abnormalities in either males or females. Histopathological examination of all organs showed scattered cell infiltration in the prostate stroma of male rats administered the test solution prepared in Manufacturing Example 1. However, this is a common lesion in rats (e.g., Gary A. Bootman, Pathology of the Fischer Rat, Academic Press, November 11, 1990). Similar findings were observed in male rats administered sterile water for injection. Therefore, it is unlikely that the cell infiltration in the prostate stroma was caused by the test solution prepared in Manufacturing Example 1.

[0066] The other findings were also considered to be unrelated to the test solution prepared in Manufacturing Example 1, given their low degree and frequency.

[0067] Based on the above, it is considered that no systemic toxicity will occur due to the test solution prepared in Manufacturing Example 1. Furthermore, the no-observed-adverse-effect level (NOAEL) of the test solution prepared in Manufacturing Example 1 was found to be 8.3 mL / kg / day.

[0068] <Test Example 3> Micronucleus Test Using Mice (1) Method The test was conducted by the Tama Laboratory of the Japan Food Research Laboratories. Male Slc:ICR mice (hereinafter simply referred to as mice) were orally administered to groups of six mice using a gastric tube at a dose of 20 or 10 mL / kg with the test solution prepared in Production Example 1 or water for injection (Japanese Pharmacopoeia). Femuric bone marrow was collected 72 hours after oral administration. Smears were prepared from the collected bone marrow, and the frequency of micronucleus appearance (%) and the frequency of immature erythrocyte appearance (%) were calculated according to Equations 1 and 2. As a positive control, cyclofosmid 50 mg / kg (Sigma-Aldrich Corporation) was administered intraperitoneally.

[0069] Formula 1

[0070] Formula 2

[0071] (2) Results (a) Micronucleus occurrence frequency The results for the micronucleus occurrence frequency (%) are shown in Table 8. A binomial test was performed on the mouse group administered the test solution prepared in Manufacturing Example 1, the mouse group administered sterile water for injection, and the mouse group administered cyclofosmid. Bonferroni correction was applied to account for multiplicity. For the dependence of the test solution prepared in Manufacturing Example 1 on the administered volume, a Cochrane-Armitage trend test (one-sided test) was performed.

[0072]

[0073] No significant difference in micronucleus frequency was observed between the mouse group administered the test solutions prepared in Manufacturing Example 1 (20 mg / kg, 10 mg / kg) and the mouse group administered sterile water for injection. Furthermore, no volume-dependent change in micronucleus frequency was observed for the test solutions prepared in Manufacturing Example 1. The mouse group administered cyclofosmid showed a significantly increased micronucleus frequency compared to the mouse group administered sterile water for injection.

[0074] (b) Regarding the frequency of immature red blood cells, the results for the frequency of immature red blood cells (%) are shown in Table 9. A Mann-Whitney test was performed for statistical analysis.

[0075]

[0076] No significant difference was observed in the frequency of immature red blood cells between the mouse group administered with the test solutions prepared in Manufacturing Example 1 (20 mg / kg, 10 mg / kg) and the mouse group administered with sterile water for injection. Furthermore, the mouse group administered with cyclofosmid showed a significantly increased frequency of immature red blood cells compared to the mouse group administered with sterile water for injection.

[0077] (3) Discussion Based on the above, it is considered that the test solution prepared in Manufacturing Example 1 does not induce chromosomal abnormalities in mouse bone marrow cells.

[0078] <Test Example 4> Reverse Mutation Test (Ames Test) (1) Method The reverse mutation test was conducted in accordance with the "Guidelines on Genotoxicity Testing of Pharmaceuticals" (November 1, 1999, Pharmaceutical Affairs Bureau Notification No. 1604) and the "Guidance on Genotoxicity Testing and Interpretation of Pharmaceuticals" (September 20, 2012, Pharmaceutical and Food Safety Bureau Notification No. 0920-2). The specific method is shown below.

[0079] Using five strains of bacteria for reverse mutation testing—Salmonella typhium TA100, TA1535, TA98, TA1537, and Escherichia coli WP2uverA—reverse mutation tests were performed on the test solution of Production Example 1 using either a non-metabolic activation method or a metabolic activation method.

[0080] Each of the five strains was divided into 1 x 10 9 The cultures were incubated at 37°C in 15 mL of nutrient broth culture medium with a rotational incubation method to achieve a concentration of 1 / mL or higher. Next, the test solution of Production Example 1 was progressively diluted using sterile water for injection. Then, 0.1 mL of the diluted test solution of Production Example 1 was added to the culture medium in which the bacterial strain was cultured. Subsequently, in the non-metabolic activation method, 0.5 mL of PBS (phosphorate-buffed saline) was added. In the metabolic activation method, 0.5 mL of S9 mix was added. The composition of S9 mix (for reverse mutation testing) is shown in Table 10.

[0081]

[0082] In the non-metabolic activation method, AF-2 ((2-Furyl)-3-(5-nitro-2-furyl)acrylamide), NaN 3 (sodium azide) or 9-AA (9-Aminoacridine hydrochloride monohydrate) was used as a positive control. In the metabolic activation method, 2-AA (2-Aminoanthracene) was used as a positive control.

[0083] Finally, the mixture was shake-cultured at 37°C for 20 minutes, and the test solution of Production Example 1 was spread on minimal glucose agar medium to achieve concentrations of 5000, 2500, 1250, 625, 313, and 0 μg / plate. After culturing at 37°C for 48 hours, the number of colonies that emerged due to reverse mutation was counted.

[0084] (2) Results The results of the reverse mutation test by the non-metabolic activation method are shown in Table 11, and the results of the reverse mutation test by the metabolic activation method are shown in Table 12.

[0085]

[0086]

[0087] When the average number of colonies increased to 2 times or more compared with the negative control and a dose-dependent relationship was observed, the gene mutagenicity was judged as positive. When the average number of colonies was less than 2 times that of the negative control, the gene mutagenicity was judged as negative. As a result, as shown in Table 5 and Table 6, the gene mutagenicity of the test solution of Production Example 1 was negative in both the non-metabolic activation method and the metabolic activation method.

[0088] (3) Discussion From the above, the gene mutagenicity of the test solution of Production Example 1 was determined to be negative.

[0089] <Test Example 5> Chromosome aberration test using cultured cells by the short-term treatment method (1) Method The chromosome aberration test using cultured cells followed the "Guidelines on Genotoxicity Tests for Pharmaceuticals" (November 1, 1999, Pharmaceutical Affairs Examination No. 1604) and the "Guidance on Genotoxicity Tests and Interpretation for Pharmaceuticals" (September 20, 2012, Pharmaceutical and Food Safety Bureau Examination Division Notification No. 0920-2). The specific method is shown below.

[0090] Using Chinese hamster lung fibroblasts (hereinafter referred to as CHL / IU cells), chromosomal aberration tests were performed using either a non-metabolic activation method or a metabolic activation method with the test solution of Production Example 1 using a short-time treatment method. Eagle's Minimum Essential Medium (containing 10% FBS) was used as the cell culture medium.

[0091] CHL / IU cells were detached by 0.25% trypsin treatment. Next, 2 × 10⁻⁶ cells were separated. 4 Cells were sown in 60mm dishes at 37°C and 5% CO2. 2 The cells were cultured under the following conditions for three days. Next, the test solution of Production Example 1 was diluted stepwise using cell culture medium. In the non-metabolic activation method, the culture medium was changed using 3 mL of the test solution of Production Example 1. In the metabolic activation method, the culture medium was changed using a mixture of 2.5 mL of the diluted test solution of Production Example 1 and 0.5 mL of S9 mix (for chromosome aberration testing). In the non-metabolic activation method, mitomycin C (Kyowa Hakko Kirin Co., Ltd.) was added at a concentration of 0.05 μg / mL as a positive control. In the metabolic activation method, Benzo[a]pyrene was added at a concentration of 10 μg / mL as a positive control. The composition of S9 mix (for chromosome aberration testing) is shown in Table 13.

[0092]

[0093] The cell proliferation rate in each dilution series was measured, with the value set to 100% when the test solution from Preparation Example 1 (0 mg / mL) of cultured cells was added. Similarly, chromosome samples were prepared using cultured cells, and chromosomal abnormalities were observed.

[0094] (2) Results The results of observing cell proliferation rate and chromosomal abnormalities using the non-metabolic activation method are shown in Table 14, and the results of observing cell proliferation rate and chromosomal abnormalities using the metabolic activation method are shown in Table 15.

[0095]

[0096]

[0097] The incidence of chromosomal structural abnormalities and the incidence of cells with numerical chromosomal abnormalities (ploidy) in cells treated with the test solution of Production Example 1 was less than 5% in both the non-metabolic activation method and the non-metabolic activation method. The same was true for cells not treated with the test solution of Production Example 1. On the other hand, the positive control showed chromosomal abnormality induction in both the non-metabolic activation method and the non-metabolic activation method.

[0098] (3) Discussion Based on the above, the chromosomal abnormality of the test solution of Production Example 1 was determined to be negative by the short-time treatment method.

[0099] <Test Example 6> Chromosome aberration test using cultured cells by continuous processing method (1) Method A chromosome aberration test was performed using the continuous processing method of the test solution from Manufacturing Example 1 by metabolic activation method, similar to Test Example 5. The cultured cells and cell culture medium used were the same as in Test Example 5.

[0100] Cells were cultured for 3 days in the same manner as in Test Example 5. Next, the test solution from Production Example 1 was diluted stepwise using cell culture medium. Then, after changing the culture medium with 5 mL of the test solution from Production Example 1, the cells were cultured for another 3 days. As a positive control, mitomycin C (Kyowa Hakko Kirin Co., Ltd.) was added at a concentration of 0.05 μg / mL.

[0101] The cell proliferation rate in each dilution series was measured, with the value set to 100% when the test solution from Preparation Example 1 (0 mg / mL) of cultured cells was added. Similarly, chromosome samples were prepared using cultured cells, and chromosomal abnormalities were observed.

[0102] (2) Results: The observed cell proliferation rate and chromosomal abnormalities are shown in Table 16.

[0103]

[0104] The incidence of chromosomal structural abnormalities and the incidence of cells with numerical chromosomal abnormalities (ploidy) in cells treated with the test solution of Production Example 1 was less than 5%. The same was true for cells not treated with the test solution of Production Example 1. On the other hand, the positive control showed chromosomal abnormality induction.

[0105] (3) Discussion Based on the above, the chromosomal abnormality of the test solution of Production Example 1 was determined to be negative by the continuous processing method.

[0106] Tests 1 to 6 confirmed that oral ingestion of the composition of the present invention poses no health risks. The functionality of the composition of the present invention was further confirmed in Tests 7 and 8.

[0107] <Test Example 7> Evaluation of cell viability in a three-dimensional culture system for hepatocellular carcinoma cell lines (CD-D ST method) The test solution obtained in Production Example 1 was subjected to an in vitro test using the human hepatocellular carcinoma cell line Hep G2 to evaluate its anticancer effect.

[0108] This study employed the Collagen gel droplet embedded culture drug sensitivity test (CD-DST method). Specifically, Hep G2 cells were divided into 3.5 × 10⁶ cells. 6 Prepare a cell / mL suspension and mix it with the following components of the Collagen Drop Kit (Primastar® KIT) (Kurabo Industries Ltd., Osaka): Solution A (Collagen Cellmatrix Type CD), Solution B (10x concentrated F-12 medium), and Solution C (reconstitution buffer) in an 8:1:1 ratio (volume). Mix the prepared cell suspension to 1 / 10 of its original concentration, and drop 30 μL into each well of a 6-well microplate. Store at 37°C and CO2. 2 The samples were incubated at 5% humidity and 91% moisture for 1 hour (Kobayashi et al. 2001). Then, 3 mL of DMEM medium was added to each well and incubated for 24 hours. 30 μL each of 1% and 10% diluted test solutions were added, and incubated for another 24 hours. Finally, the medium in each well was replaced with 4 mL of DMEM, and the samples were incubated at 37°C and CO2. 2 The mixture was shaken in a plate mixer for 10 minutes at 5% humidity and 91% moisture, and the same procedure was repeated. Furthermore, the culture medium in each well was replaced with 4 mL of PCM-2 medium (Primastar® KIT) (Kurashiki Spinning Co., Ltd., Osaka), and the culture was performed for 7 days, with the liquid being changed with 4 mL of PCM-2 medium every 2-3 days. Each well was then replaced with 3 mL of DMEM medium containing 0.1% collagenase (Collagenase L, Nitta Gelatin Co., Ltd., Osaka), and cultured at 37°C and CO2. 2The cells were shaken in a plate mixer for 30 minutes at 5% humidity and 91% moisture. The collagen-removed cells were stained with trypan blue (Wako Pure Chemical Industries, Osaka), and the cell count was measured using a hemocytometer. The number of viable cells was calculated using the control cell viability as 100%. Based on the obtained data, the cell viability rate was calculated using the following formula: Viability rate (%) = (Number of unstained cells / Total number of cells) × 100

[0109] The cell viability rates for each group were as follows: Cell viability rate (%) Control (untreated) 100.0 1% treatment group 85.9 10% treatment group 84.9

[0110] The results above confirm that the composition of the present invention has the effect of significantly reducing the survival rate of hepatocellular carcinoma cells. In particular, even at a concentration of 1%, the survival rate was suppressed to 85.9%, suggesting the excellent antitumor activity of this composition.

[0111] Furthermore, when the test solution was administered to normal primary cultured cells (not cancer cells) and cultured, no cell death was observed. Therefore, the cell viability-inhibiting effect of the composition of the present invention, as demonstrated in this test example, is specific to cancer cells.

[0112] <Test Example 8> Application of the test solution to a breast cancer patient The tumor reduction effect and side effect reduction effect were evaluated when the test solution according to the present invention was used in combination with standard neoadjuvant chemotherapy (doxorubicin, docetaxel, etc.), surgery, postoperative radiotherapy, and molecular targeted therapy as adjuvant therapy (trastuzumab emtansine, etc.) in one patient diagnosed with HER2-positive breast cancer (with lymph node metastasis).

[0113] <Patient and Treatment Plan> Patient: Breast cancer (HER2 type), lymph node metastasis (3 locations, largest 1.5 cm), chest tumor largest 5.5 cm (condensed). Treatment Plan: Preoperative chemotherapy: - Doxorubicin-containing chemotherapy regimen administered every 3 weeks for 4 times (from day 0 to approximately 2 months after the start of treatment). - Docetaxel and molecular targeted drug (anti-HER2 drug) administered every 3 weeks for 4 times (from approximately 3 months to approximately 5 months after the start of treatment). Surgery: Breast cancer removal surgery (approximately 6 months after the start of treatment). Postoperative radiotherapy: A total of 30 radiotherapy sessions were performed (from approximately 7.5 months to approximately 9 months after the start of treatment). Postoperative adjuvant therapy: Molecular targeted drug (trastuzumab emtansine) administered every 3 weeks for 14 times (from approximately 6.5 months to approximately 16 months (approximately 1 year and 4 months) after the start of treatment). During the period of the above-mentioned neoadjuvant chemotherapy, postoperative radiotherapy, and postoperative adjuvant therapy, the patient drank 100 ml of the test solution daily.

[0114] <Results: 50 days after the start of treatment (doxorubicin administration period for neoadjuvant chemotherapy)> 1. Tumor status Before the start of treatment, the maximum diameter of the thoracic tumor was 5.5 cm (condensed state), and there were three lymph node metastases with a maximum diameter of 1.5 cm. 50 days after the start of treatment, the thoracic tumor had shrunk to less than 3.0 cm in maximum diameter, and cavitation was observed inside. Lymph node metastases had decreased to one location, and their maximum diameter had shrunk to 1.0 cm.

[0115] 2. Hematological findings and weight: Before and after the start of treatment, white blood cell count and mineral levels remained within normal ranges, and in particular, an improvement trend was observed after the start of neoadjuvant chemotherapy compared to before treatment. Weight was also maintained throughout the treatment period.

[0116] 3. Subjective Symptoms and Side Effects Before the start of treatment, pain in the affected area, numbness in the arm, and frequent fever were observed. Fifty days after the start of treatment, these pre-treatment pains had disappeared. For about one week after administration of neoadjuvant chemotherapy including doxorubicin, side effects such as stomach upset, headache, general pain, and edema were observed, but these did not interfere with daily life. The wide range of symptoms observed before treatment, such as nausea, headache, chest pain, general pain, hair loss, edema, nail discoloration, stomatitis, and fever, were significantly reduced after the start of neoadjuvant chemotherapy.

[0117] <Results: Approximately 12 months (1 year) after the start of treatment (during the administration of trastuzumab emtansine as adjuvant therapy after surgery)> The patient was able to continue working and live a normal daily life throughout the treatment period without falling into the severe conditions (e.g., inability to work, being bedridden, etc.) that would be expected if the patient received standard, similar multidisciplinary treatment (preoperative chemotherapy, surgery, postoperative radiotherapy, postoperative adjuvant therapy). The ability to maintain a daily life cycle allowed the patient to continue all planned treatments.

[0118] The results of this study, compared to adverse events that are generally likely to occur with standard multidisciplinary treatment (preoperative chemotherapy using doxorubicin, docetaxel, etc., surgery, radiotherapy, and adjuvant therapy using trastuzumab emtansine, etc.), are as follows: (1) Fever: Standard treatment often results in fever accompanied by fatigue, but in this study, fever exceeding 37.5°C occurred only a few times. (2) Appetite: Standard treatment commonly results in loss of appetite due to nausea, but in this study, patients were able to eat normally and did not need to consume so-called sick food. (3) General condition: Standard treatment can result in situations where patients are unable to get up due to generalized pain, but this did not occur in this study. (4) Edema: Standard treatment can result in generalized edema, but this did not occur in this study. (5) Hair loss: Hair loss is inevitable with standard treatment (especially when doxorubicin and docetaxel are administered), and although hair loss was observed in this study, hair regrowth was rapid, and the regenerated hair was healthy (normally, regenerated hair after chemotherapy tends to be thin and curly). (6) Mucosal damage: With standard treatment, the mucous membrane becomes fragile, and bleeding from the gums and nose may occur repeatedly, and although fragility of the mucous membrane was observed in this study, problems such as bleeding could be avoided by avoiding irritants. (7) Olfactory abnormalities: With standard treatment, patients may become sensitive to smells and have difficulty eating, but in this study, improvement was observed after the end of the doxorubicin administration period of neoadjuvant chemotherapy (approximately 2 months after the start of treatment). (8) Eczema: Eczema may occur with standard treatment, but in this study it was mild. (9) Feasibility of surgery: With standard treatment, surgery may be difficult if the tumor reduction effect of neoadjuvant chemotherapy is insufficient, but in this study, surgery (approximately 6 months after the start of treatment) could be performed as planned. (10) Leukopenia: Leukopenia is frequently observed in standard treatment (especially during neoadjuvant chemotherapy), but no significant leukopenia was observed in this study. (11) Thrombocytopenia: Thrombocytopenia may be observed in standard treatment (especially when trastuzumab emtansine is administered as adjuvant therapy after surgery), but in this study, the decrease was only slight and did not reach a level requiring a reduction in the dosage of the medication.(12) Decreased mineral content: A decrease in mineral content may be observed in standard treatment, but this did not occur in this study. (13) Liver dysfunction: Liver function test values ​​may worsen in standard treatment (especially when trastuzumab emtansine is administered as adjuvant therapy after surgery), but although worsening was observed in this study, it did not reach a level requiring a reduction in the dosage of the medication. (14) Cardiac dysfunction: The risk of heart failure may increase in standard treatment (especially when doxorubicin is administered), but in this study, only mild tachycardia was observed, and it did not reach a level that interfered with daily life. (15) Radiation pneumonitis: There is a risk of radiation pneumonitis when postoperative radiation therapy is performed in standard treatment (approximately 7.5 to 9 months after the start of treatment in this study), but this situation did not occur in this study. (16) Radiation skin damage: When postoperative radiation therapy is performed in standard treatment, skin necrosis and discoloration may remain, but in this study, the skin condition recovered well with the use of lotion. (17) Mental state: While standard treatment can sometimes lead to depression, in this study patients were able to continue working without taking leave. (18) Hot flashes: While hot flashes can persist with standard treatment (especially hormone therapy), this did not occur in this study. (19) Sleep disorders: While standard treatment can sometimes lead to insomnia, good sleep was maintained in this study.

[0119] <Discussion> In this example, patients diagnosed with HER2-positive breast cancer (with lymph node metastasis) were given the test solution according to the present invention continuously in parallel with standard multidisciplinary treatment (preoperative chemotherapy, surgery, postoperative radiotherapy, and postoperative adjuvant therapy). As a result, at a relatively early stage of 50 days after the start of treatment (doxorubicin administration during preoperative chemotherapy), a significant reduction in the size of the primary tumor in the chest (from 5.5 cm to less than 3.0 cm) and cavitation, as well as a decrease in the number (from 3 to 1) and size of lymph node metastases, were observed. This suggests that the test solution enhanced the effect of existing preoperative chemotherapy with doxorubicin, etc., or that the test solution itself has a direct antitumor effect.

[0120] Furthermore, it is noteworthy that the patient's quality of life (QOL) was maintained at an extremely good level throughout the entire treatment period (approximately 16 months from the start of treatment), including neoadjuvant chemotherapy (doxorubicin, docetaxel, etc.), surgery, postoperative radiotherapy, and postoperative adjuvant therapy (trastuzumab emtansine, etc.). Typically, similar multidisciplinary treatments frequently cause a wide range of side effects, such as severe anorexia, nausea and vomiting, general malaise, fever due to immunosuppression (leukopenia), hair loss, various mucosal damages, cardiotoxicity (doxorubicin, etc.), liver dysfunction and thrombocytopenia (trastuzumab emtansine, etc.), radiation-induced skin damage and pneumonia, and mental depression, making it difficult for patients to work or carry out normal daily activities. In some cases, side effects can become severe, making it difficult to continue the planned treatment, or necessitating a reduction, change, or discontinuation of the treatment regimen.

[0121] However, in this study, with the exception of temporary, minor discomfort after anticancer drug administration, the occurrence of serious side effects was suppressed, patients experienced the disappearance of pain experienced before the start of treatment, and were able to lead normal daily lives, including work, without major hindrance during the treatment period. In particular, the fact that white blood cell counts and mineral levels remained within normal ranges and even showed an improving trend, that weight was maintained, that hair regrowth after hair loss, which should occur frequently, was good, that fevers exceeding 37.5°C were rare, that patients were able to eat normally, that no serious pneumonia or skin disorders occurred associated with postoperative radiotherapy, that thrombocytopenia and liver dysfunction in postoperative adjuvant therapy were minor, that the impact on cardiac function was not clinically problematic, and that patients were mentally stable and did not need to take leave from work, are all significant improvements compared to the standard treatment course. These facts strongly suggest that the test solution may have reduced the side effects associated with multidisciplinary treatment (preoperative chemotherapy, postoperative radiotherapy, and postoperative adjuvant therapy) and significantly reduced the physical and mental burden on patients.

[0122] Although this study is a single-case report without a placebo control group, the observed degree of tumor reduction, the significant reduction in a wide range of side effects, and the maintenance of quality of life (QOL) are considered difficult to explain solely by the effects of standard treatment. In particular, in cancer treatment, controlling side effects and maintaining and improving the patient's QOL, as well as improving treatment efficacy, are extremely important for the continuity and success of treatment. The combination therapy with this test solution has shown the potential to provide a dual benefit: not only a direct anti-cancer effect of tumor reduction, but also the maintenance of QOL through the reduction of side effects, and consequently, support for the completion of treatment.

[0123] Based on the above results, the composition of the present invention is expected to have an anticancer effect in itself in the treatment of malignant tumors such as breast cancer, and to reduce side effects associated with standard multidisciplinary treatment (preoperative chemotherapy, surgery, postoperative radiotherapy, and postoperative adjuvant therapy), thereby improving the patient's quality of life.

[0124] This invention can be applied to supplements and pharmaceuticals.

Claims

1. An oral composition comprising the culture supernatant of Escherichia coli in which the gene ypjD(b2611) is unable to be expressed due to a mutation.

2. The composition according to claim 1, which is a beverage.

3. The composition according to claim 1, comprising the culture supernatant.

4. The composition according to any one of claims 1 to 3, which is an anticancer composition.

5. An anticancer composition comprising the culture supernatant of Escherichia coli in which the gene ypjD(b2611) is unable to be expressed due to a mutation.